Stockscreener 앱 받기
2.40
2.44%
-0.06
전일 마감가:
$2.46
열려 있는:
$2.47
하루 거래량:
1.34M
Relative Volume:
0.93
시가총액:
$308.82M
수익:
$514.70M
순이익/손실:
$2.72M
주가수익비율:
-15.10
EPS:
-0.1589
순현금흐름:
$17.08M
1주 성능:
+1.69%
1개월 성능:
-2.83%
6개월 성능:
-42.99%
1년 성능:
-45.45%
1일 변동 폭
$2.36
$2.47
1주일 범위
$2.345
$2.59
52주 변동 폭
$2.04
$7.0771
Organogenesis Holdings Inc Stock (ORGO) Company Profile
명칭
Organogenesis Holdings Inc
전화
781-575-0775
주소
85 DAN ROAD, CANTON, MA
Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORGO
Organogenesis Holdings Inc
|
2.40 | 308.82M | 514.70M | 2.72M | 17.08M | -0.1589 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-28 | 개시 | Lake Street | Buy |
| 2024-02-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-08-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-08-26 | 재개 | Credit Suisse | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
| 2019-04-17 | 개시 | Oppenheimer | Outperform |
| 2019-04-11 | 개시 | SunTrust | Buy |
모두보기
Organogenesis Holdings Inc 주식(ORGO)의 최신 뉴스
Organogenesis (ORGO) AGM 2026 Summary - Quartr
Organogenesis (ORGO) Proxy filing Summary - Quartr
Organogenesis (ORGO) Q1 2026 earnings summary - Quartr
Organogenesis (ORGO) Q1 2025 earnings summary - Quartr
Organogenesis schedules Aug. 6 results call after market close - Stock Titan
Organogenesis Holdings outlines regenerative medicine path as investors weigh long-term growth - ad-hoc-news.de
Organogenesis Amnuvx Gets FDA Review for Knee OA - AllSci
FDA accepts Organogenesis’ application for knee osteoarthritis treatment - Investing.com
Organogenesis' Biologics License Application for ReNu Accepted by FDA for Review - Moomoo
FDA accepts Organogenesis' Biologics License Ap... - Pluang
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis - The Manila Times
Organogenesis wins FDA review for ReNu, a knee osteoarthritis treatment - Stock Titan
ORGO Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesCFO Commentary Report - dars.gov.et
ORGO Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesUpward Estimate Revision - dars.gov.et
Enterprise value to revenue forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to book forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to sales forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis | 10-K: FY2025 Annual Report - Moomoo
Enterprise value to EBITDA forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Price to earnings forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Price to earnings forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM: ORGO) added to Russell 2000 Value Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
Organogenesis Holdings, Inc. Class A Actuals & Estimates (NASDAQ:ORGO) - TradingView
ORGO Forecast — Price Target — Prediction for 2027 - TradingView
Organogenesis Holdings Inc (ORGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Organogenesis Holdings (ORGO) Edges Higher as Shares Approach Key ResistanceVolume Breadth - dars.gov.et
Organogenesis Holdings Inc (ORGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Organogenesis Holdings Inc (ORGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Spotlight On 3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
Organogenesis Holdings Inc (ORGO) Institutional Confidence - TradingKey
Organogenesis Holdings Inc (ORGO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Organogenesis Holdings Inc (ORGO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Organogenesis Holdings Inc - TradingKey
Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Organogenesis Holdings Inc (ORGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Organogenesis re-elects Garrett Lustig to its board - TradingView
Organogenesis (NASDAQ: ORGO) investors reelect full board and approve pay - Stock Titan
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It - GlobeNewswire
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked - Seeking Alpha
ORGO Q1 2026 Earnings: Significant EPS Miss Highlights Persistent ChallengesGuidance Downgrade Alert - dars.gov.et
ORGO Q1 2026 Earnings: EPS Misses Estimates by 29.66% as Losses WidenNegative Surprise Momentum - newsline.com
Organogenesis Holdings (ORGO) Consolidates Near Support After Marginal DeclineVolatility Skew - newsline.com
The Body as Blueprint - lifehealth.com
Organogenesis Holdings Inc (ORGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Organogenesis Holdings Inc 주식 (ORGO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Driscoll Michael Joseph | Director |
Mar 09 '26 |
Buy |
2.67 |
10,000 |
26,688 |
225,707 |
| NUSSDORF GLENN H | Director |
Dec 16 '25 |
Sale |
5.14 |
200,000 |
1,027,060 |
2,565,591 |
3.42%
0.81%
자본화:
|
볼륨(24시간):